Table 1 Characteristics of the study cohort.

From: A FinnGen pilot clinical recall study for Alzheimer’s disease

 

AD (n = 15)

MCD (n = 12)

p-value

Age (years)

73.0 (8.8)

72.5 (8.3)

0.895

Sex, females/males (n)

8/7

5/7

0.830

APOE4 carrier (n)

10

3

0.171

MMSE (score)

24.0 (7.6)

24.1 (6.7)

0.977

In-person tests

 CERAD immediate recall (score)

14.6 (6.6)

15.2 (6.0)

0.812

 CERAD delayed recall (score)

4.0 (2.8)

5.0 (2.4)

0.343

 TMT-A (s)

84.3 (54.2)

83.6 (35.0)

0.973

 TMT-B (s)

178.1 (83.9)

215.2 (83.8)

0.337

 Semantic fluency (score)

18.1 (7.3)

18.0 (8.2)

0.963

Computer-based tests

 cCOG immediate recall (score)

13.6 (6.2)

12.6 (5.1)

0.666

 cCOG delayed recall (score)

3.5 (3.2)

4.1 (2.8)

0.632

 cCOG TMT-A modified (s)

98.8 (74.1)

81.1 (33.6)

0.567

 cCOG TMT-B modified (s)

231.6 (87.4)

261.0 (91.6)

0.525

Phone-based tests

 TELE total (score)

15.3 (4.9)

17.2 (4.9)

0.346

 TICS-m immediate recall (score)

14.5 (9.6)

14.2 (6.6)

0.927

 TICS-m delayed recall (score)

3.8 (4.0)

2.6 (2.4)

0.365

 Semantic fluency (score)

15.1 (6.8)

17.2 (6.7)

0.446

  1. Data are given as mean and standard deviation for Alzheimer’s disease (AD) and mild cognitive disorder (MCD) groups separately. APOE4 carrier status was available for 23 (14AD/9MCD) and MMSE, CERAD immediate and delayed recall, cCOG immediate and delayed recall, and in-person verbal fluency data was available for 26 (14AD/12MCD) participants. In-person TMT-A was available for 25 (14AD/11MCD), in-person TMT-B for 20 (11AD/9MCD), cCOG TMT-A for 17 (10AD/7MCD), and cCOG TMT-B for 17 (11AD/6MCD) participants.
  2. APOE apolipoprotein E, cCOG computerized cognitive testing, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, MMSE Mini Mental State Examination, TELE telephone assessment for dementia, TICS-m modified telephone interview for cognitive status with three learning trials of the 10-word list, TMT-A/B trail making test parts A and B.